

## *References*

## 9. REFERENCES

1. WHO. International drug monitoring: the role of national centres. Tech Rep Ser WHO 1972, p 498.
2. Muehlberger N, Schneeweiss S, Hasford J. Adverse drug reaction monitoring-cost and benefit considerations. Part I: frequency of adverse drug reactions causing hospital admissions. *Pharmacoepidem & drug safety* 1997; 6 (S3): 71-77.
3. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients-excess length of stay, extra costs and attributable mortality. *JAMA* 1997; 277: 301-6.
4. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. *JAMA* 1998; 279: 1200-1205.
5. Johnson JA, Bootman JL. Drug-related morbidity and mortality: a cost-of-illness model. *Arch Intern Med.* 1995; 155: 1949-56.
6. Kennedy DL, Goldman SA, Lillie RB. Spontaneous reporting in the United States. In: Strom BL, editor. *Pharmacoepidemiology*. 3rd ed. Chichester: John Wiley and Sons, Ltd.; 2000. p. 151-74.
7. WHO. International drug monitoring. The importance of pharmacovigilance. Safety monitoring of medicinal products. Geneva: WHO 2002.
8. M. Liu, M. E. Matheny, Y. Hu, H. Xu. Data mining methodologies for Pharmacovigilance. *ACM SIGKDD explorations newsletter* 2012; 14 (1): 35-42.

9. Walker SR, Lumley CE. The attitudes of general practitioners to the monitoring and reporting of adverse drug reactions. *Pharmaceut Med* 1986; 1: 195-203.
10. Egberts TCG, Smulders M, de Koning FHP, Meyboom RH, Leufkens HG. Can adverse drug reactions be detected earlier? A comparison of reports by patients and professionals. *BMJ* 1996; 313: 530-1.
11. Martin RM, Kapoor KV, Wilton LV, Mann RD. Underreporting of suspected adverse drug reactions to newly marketed (“black triangle”) drugs in general practice: observational study. *BMJ* 1998; 317: 119-20.
12. Smith CC, Bennett PM, Pearce HM, Harrison PI, Reynolds DJ, Aronson JK, Grahame-Smith DG. Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. *Br J Clin Pharmacol* 1996; 42 (4): 423-9.
13. Moride Y, Haramburu F, Requejo AA, Begaud B. Under-reporting of adverse drug reactions in general practice. *Br J Clin Pharmacol* 1997; 43 (2):177-81.
14. Lumley CE, Walker SR, Hall GC, Staunton N, Grob PR. The underreporting of adverse drug reactions seen in general practice. *Pharmaceut Med* 1986; 1:205-12.
15. Figueiras A, Tato F, Fontainas J, Gestal-Otero JJ. Influence of physicians’ attitudes on reporting adverse drug events: a case-control study. *Med Care*. 1999; 37: 809-814.
16. Williams D, Feely J. Underreporting of adverse drug reactions: attitudes of Irish doctors. *Ir J Med Sci*. 1999; 168: 257-261.

17. Perlik F, Slanar O, Smid M, Petracek J. Attitude of Czech physicians to adverse drug reaction reporting. *Eur J Clin Pharmacol.* 2002; 58:367-369.
18. Hasford J, Goettler M, Munter KH, Muller-Oerlinghausen B. Physicians' knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions. *J Clin Epidemiol.* 2002; 55: 945-950.
19. H. S. Rehan, K. Vasudev, and C. D. Tripathi, "Adverse drug reaction monitoring: knowledge, attitude and practices of medical students and prescribers," *The National Medical Journal of India*, vol. 15, no. 1, pp. 24-26, 2002. View at Scopus.
20. Vikas Dhikav, Sindhu Singh, KS Anand. Adverse Drug Reaction Monitoring In India. *JIACM*, 2004; 5 (1), 27-33.
21. Amrita P, Kharbanda B. Knowledge, attitude and skills of nurses of Delhi towards adverse drug reaction reporting. *Indian J Pharm Pract* 2012; 5: 45-51.
22. Blenkinsopp A, Wilkie P, Wang M, Routledge P.A. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. *Br J Clin Pharmacol.* Feb 2007; 63 (2): 148-156.
23. Margraff F, Bertram D. Adverse drug reaction reporting by patients: an overview of fifty countries. *Drug Saf.* 2014. Jun; 37 (6): 409-19.
24. Edwards I, Aronson J. Adverse drug reactions: definitions, diagnosis, and management. *The Lancet.* Oct 2000; 356, 1255-1259.
25. WHO Collaborating Centre for International Drug Monitoring 1992, International monitoring of adverse reactions to drugs: adverse reaction terminology. Uppsala, Sweden.

26. Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In: Davies DM, editor. Textbook of adverse drug reactions. Oxford: Oxford University Press; 1977. p. 10.
27. Aronson JK. Drug therapy. In: Haslett C, Chilvers ER, Boon NA, Colledge NR, Hunter JAA, editors. Davidson's principles and practice of medicine. 19th ed. Edinburgh: Elsevier Science; 2002. p. 147-63.
28. Gell PGH, Coombs RRA. Clinical Aspects of Immunology. 1st ed. Oxford, England: Blackwell; 1963.
29. ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Clinical Data Safety Management: Definitions and Standards for Expedited Reporting E2A. Geneva: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; 1994. Available from: [http://www.ich.org/fileadmin/Public\\_Web\\_Site/ ICH\\_Products /Guidelines/Efficacy/E2A/Step4/E2A\\_Guideline.pdf](http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2A/Step4/E2A_Guideline.pdf). Accessed 24 Aug 2014.
30. Hartwig S.C, Siegel J, Schneider. Preventability and severity assessment in reporting adverse drug reactions. Am. J. Hosp. Pharm 1999; 49: 2229-2232.
31. Hoigne et al. Time pattern of allergic reactions to drugs. Agents Actions Suppl 1990; 29: 39-58.
32. Leach S, Roy SS. Adverse drug reactions: an investigation on an acute geriatric ward. Age and Ageing 1986; 15: 241-246.
33. Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 2003; 57(1): 6-14.

34. Anantharajau A, Feller A, Chedid A. Aging Liver. *Gerontology* 2002; 48: 342-53.
35. Castleden CM, George CF. The effect of ageing on the hepatic clearance of propranolol. *Br J Clin Pharmacol* 1979; 25: 297-305.
36. Todd PA, Fitton A. Perindopril. A Review of its pharmacological properties and therapeutic use. *Drugs* 1991; 42: 90-114.
37. Gurwitz J, Avorn J. The ambiguous relationship between aging and adverse drug reactions. *Ann Int Med* 1991; 114: 956-966.
38. Seidl LG, Thornton GF, Smith JW, Cluff LE. Studies on the epidemiology of adverse drug reactions. III. Reactions in patients on a general medical service. *John Hopkins Med J* 1966; 119: 299-315.
39. Moore N, Leocointre D, Noblet C, Mabilille M. Frequency and cost of serious adverse drug reactions in a department of general medicine. *Br J Clin Pharmacol* 1998; 45: 301- 308.
40. Bowman L, Carlstedt BC, Black CD. Incidence of adverse drug reactions in adult medical inpatients. *Can J Hosp Pharm* 1994; 47(5): 209-216.
41. Van den Bemt PMLA, Egberts ACG, Lenderink AW, et al. Risk factors for the development of adverse drug events in hospitalized patients. *Pharm World Sci* 2000; 22(2): 62-66.
42. Gupta A, Waldhauser LK. Adverse Drug Reactions from Birth to Early Childhood. *Pediatr Clin North Am* 1997; 44: 79-92.
43. Nahata MC. Paediatrics Pharmacotherapy A Pathophysiologic Approach. In: Dipiro JT, Talbert R, Yee GC, Matzake GR, Wells BG, Posey ML. editors. *Stanford Ct: Appleton & Lange; 1999. p. 44-51.*

44. Bowman L, Cardstedt BC, Hancock EF, Black CD. Adverse drug reaction (ADR) occurrence and evaluation in elderly in-patients. *Pharmacoepidemiol Drug saf* 1996; 5: 9-18.
45. Fattinger K, Roos M, Veregeres P, *et al.* Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. *Br J Clin Pharmacol* 2000; 49: 158-167.
46. Kando JC, Yonkers KA, Cole JO. Gender as a risk factor for adverse events to medications. *Drugs* 1995; 50: 1-6.
47. Drici M-D, Clement N. Is gender a risk factor for adverse drug reactions? *Drug safety* 2001; 24: 575-585.
48. Schwartz JB. The influence of sex on pharmacokinetics. *Clin pharmacokinet* 2003; 42(2): 107-121.
49. Lehmann MH, Hardy S, Archibald D, MacNeil DJ. QTc Prolongation with d,l-sotalol in women versus men. *Am J Cardiol* 1999; 83(3): 354-9.
50. Roden DM. Drug-induced prolongation of the QT interval. *NEJM* 2004; 350(10): 1013-1022.
51. Piazza LA, Markowitz JC, Kocsis JH, *et al.* Sexual functioning in chronically depressed Roden DM. Drug-induced prolongation of the QT interval. *NEJM* 2004; 350 (10): 1013-1022.
52. Gurwitz JH. Polypharmacy-A new paradigm for quality drug therapy in the elderly. *Arch Int Med* 2004; 164: 1957-1959.
53. Onder G, Gambassi G, Scales C, *et al.* Adverse drug reactions and cognitive function among hospitalized older adults. *Eur J Clin Pharmacol* 2002; 58: 371-377.

54. Gholami K, Shalviri G. Factors associated with preventability, predictability and severity of adverse drug reactions. *Ann Pharmacother* 1999; 33: 236-40.
55. Nguyen JK, Fouts MF, Kotabe SE. Polypharmacy as a risk factor for adverse drug reactions in geriatric nursing home residents. *Am J Geriatr Pharmacother* 2006; 4(1): 36-41.
56. Routledge PA, O'Mahony MS, Woodhouse KW. Adverse drug reactions in elderly patients. *Br J Clin Pharmacol* 2003; 57: 121-6.
57. Douchet J, Chassagne P, Trivalle C, et al. Drug-drug interactions related to hospital admissions in older adults: a prospective study of 1000 patients. *J Am Ger Soc* 1996; 44: 944-8.
58. Lindley CM, Tully MP, Paramsothy V, et al. Inappropriate medication is a major cause of adverse drug reactions in elderly patients. *Age Ageing* 1992; 21: 294-300.
59. Wiffen P, Gill M, Edwards J, Moore A. Adverse drug reactions in hospital patients. A systematic review of the prospective and retrospective studies. *Bandolier Extra* 2002; 1-16.
60. Aronson JK, Ferner RE. Joining the DoTS: new approach to classifying adverse drug reactions. *BMJ* 2003; 327: 1222-5.
61. Pirmohamed M, Kevin Park B. Genetic susceptibility to adverse drug reactions. *Trends Pharmacol Sci* 2001; 22: 298-305.
62. Ingelman Sundberg M *et al.* Polymorphic human Cytochrome P450 enzymes: an opportunity for individualized drug treatment. *Trends Pharmacol Sci* 1999; 20: 342-349.
63. Tan S *et al.* Association between  $\beta$ 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitization in moderately severe stable asthmatics. *Lancet* 1997; 350: 995-999.



64. Basile V.S. et al. Association of the Msc I polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. *Neuropsychopharmacology* 1999; 21: 17-27.
65. McCarthy TV et al. Ryanodine receptor mutations in malignant hyperthermia and central core disease. *Hum Mutat* 2000; 15: 410-417.
66. Shieh CC et al. Potassium channels: molecular defects, diseases, and therapeutic opportunities. *Pharmacol Rev* 2000; 52: 557-594.
67. Knowles SR et al. Idiosyncratic drug reactions: the reactive metabolite syndromes. *Lancet* 2000; 356: 1587-1591.
68. Applied Biopharmaceutics and pharmacokinetics; Shargel I, Yu A. editors. Stamford CT: Appleton and Lange; 1999.
69. Uchegbu I, Florence A. Adverse drug events related to dosage forms and delivery systems. *Drug safety* 1996; 14(1): 39-67.
70. Edwards JR. Pharmacological Basis of Adverse Drug Reactions. Avery's Drug Treatment. Speight T, Holford N, editors. ADIS International Ltd: Auckland, New Zealand 1997. p. 261-299.
71. Pirmohamed M et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. *British Medical Journal* 2004; 329 (7456): 15-19.
72. Davies EC et al. Adverse drug reactions in hospital in-patients: A prospective analysis of 3695 patient-episodes. *Plos One* 2009; 4 (2).
73. National Kidney Foundation, The Facts About Chronic Kidney Disease. New York, NY, 2012.
74. U.S. Renal Data System, USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End Stage Renal Disease in the United States.

- National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2011.
75. Jacob D, Marron B, Ehrlich J, Rutherford PA. Pharmacovigilance as a tool for safety and monitoring: a review of general issues and the specific challenges with end-stage renal failure patients. *Drug Healthc Patient Saf.* 2013 Apr 15; 5: 105-12.
  76. Commission on Anaesthetics. *Lancet* 1893; 1: 629-38.
  77. Rawlins MD. Pharmacovigilance: paradise lost, regained or postponed? *J R Coll Physicians Lond* 1995; 29: 41-49.
  78. Geiling EMK, Cannon PR. Pathogenic effects elixir of sulfanilamide (diethylene glycol) poisoning. *Am Med Assoc.* 1938; 111: 919-20.
  79. McBride WG. Thalidomide and congenital abnormalities. *The Lancet* 1961; 2: 1358.
  80. Routledge P. 150 years of pharmacovigilance. *The Lancet* 1998; 351: 1200-1.
  81. Venulet J, TenHam M. Methods for monitoring and documenting adverse drug. *Int J Clin Pharmacol Ther* 1996; 34: 112-129.
  82. WHO Programme for International Drug Monitoring [online]. Available from: URL: <http://www.who.unc.org/> (Accessed on 10 May 2015).
  83. Gross FH. Scientific basis of drug safety regulations. In: Auriche M *et al.*, editors. *Drug Safety, Progress and Controversies*. London: Pergamon Press; 1982. p. 9-18.
  84. Belton KJ *et al.* Attitude survey of adverse drug reaction reporting by health care professionals across the European Union. *Eur J Clin Pharmacol* 1997; 52: 423-427.

85. Goettler M, Schneeweiss S, Hasford J. Adverse drug reaction monitoring-cost and benefit considerations Part II: cost and preventability of adverse drug reactions leading to hospital admission. *Pharmacoepidemiol Drug Saf* 1997; 6 (3suppl): S79-90.
86. Storm BL. *Pharmacoepidemiology*. Philadelphia: John Wiley & Sons; 2005.
87. British Medical Association. Board of Science. Reporting adverse drug reactions: A guide to healthcare professionals; London BMA. May 2006. Available from URL: [http://www.bma.org.uk/ap.nsf/content/Adverse Drug Reactions](http://www.bma.org.uk/ap.nsf/content/Adverse_Drug_Reactions) (Accessed on 24 Aug 2014).
88. Australian Guidelines for Pharmacovigilance. Responsibilities of sponsors of Registered Medicines. Regulated by Drug Safety and Evaluation Branch; July 2003. Available from URL: <http://www.tga.gov.au/adr/pharmaco.pdf> (Accessed on 24 Aug 2014).
89. Biswas P. Pharmacovigilance; Safety matters. *Indian J Pharmacol* 2008; 40: 1-2.
90. Kulkarni RD. Reporting system for rare side effects of non-narcotic analgesics in India: Problems and opportunities. *Med Toxicol* 1986; 1: 110-3.
91. Pharmacovigilance Programme of India, National Coordination Centre. Indian Pharmacopoeia Commission. April 2011. Available from URL: <http://www.ipc.gov.in/PvPI> (Accessed on 24 Aug 2014).
92. Van Grootheest K, Olsson S, Couper M *et al*. Pharmacists' role in reporting adverse drug reactions in an international perspective. *Pharmacoepidemiol Drug Saf* 2004; 13: 457-464.
93. Van Grootheest K, de Jong-van den Berg. Patients' role in reporting adverse drug reactions. *Expert Opin Drug Saf* 2004; 3: 363-368.

94. Van Grootheest AC, Passier JL, Van Puijenbroek EP. Direct reporting of side effects by the patient: favourable experience in the first year. *Ned Tijdschr Geneesk* 2005; 149: 529-533.
95. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systemic review. *Drug saf*. 2006; 29: 385-396.
96. Martinez C, Walker A. Hypothesis testing using spontaneous reports as a source for case-control studies. *Pharmacoepidemiol drug Saf* 1995; 4: 69.
97. Council for International Organizations of Medical Sciences. Basic requirements for the use of terms for reporting adverse drug reactions. *Pharmacoepidemiol* 1992; 1: 39-45.
98. Hurwitz N, Wadeoc. Intensive hospital monitoring of adverse reaction to drugs. *BMJ* 1969; 1: 531-536.
99. Venulet J. From experimental to social pharmacology. *Int J Clin Pharmacol Ther* 1974; 10: 203-205.
100. Inman WHW. Postmarketing surveillance of adverse reactions in general practice. I: Search for new methods. II: Prescription event monitoring at the University of Southampton. *Br Med Journal* 1981; 282: 1131-1216.
101. Hurwitz AL *et al*. Public Health Service study of Reye's syndrome and medications. *J Am Med Assoc* 1987; 257(14): 1905-11.
102. Herbst AL, Robboy SJ, Scully RE, Poskanzer DC. Clear-cell adenocarcinoma of the vagina and cervix in girls: An analysis of 170 registry cases. *Am. J Obstet Gynecol* 1974; 119: 713-24.
103. Werler MM, Shapiro S, Mitchell AA. Periconceptional folic acid exposure and risk of occurrent neural tube defects. *J Am Med Assoc* 1993; 269(10): 1257-61.

104. Dowber TR, Meadors GF, Moore FE. Epidemiological approaches to heart disease: The Framingham Heart study. *Am. J Public Health* 1951; 41: 279-286.
105. Steering Committee of the Physician's Health Study Research group. Final report on the aspirin component of the Physicians Health Study. *NEJM* 1989; 321: 129-135.
106. Winooski DK, Baum C. Outpatient use of prescription sedative-hypnotic drugs in United States, 1970 through 1989. *Arch Intern Med* 1991; 151: 1779-1783.
107. Moore RA, Tramer MR, Carroll D, Wiffen PJ, McQuay HJ. Quantitative symptomatic review of topical applied non-steroidal anti-inflammatory drugs. *BMJ* 1998; 316: 333-338.
108. Talley NJ. Chronic peptic ulceration and nonsteroidal anti-inflammatory drugs: more to be said about NSAIDS? *Gastroenterol* 1992; 102: 1074-1078.
109. Olivier P, Monastruc JL. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France. *Pharmacoepidemiol Drug Saf.* 2006; 15 (11): 808-812.
110. Van Hunsel F, Härmark L, Pal S, Olsson S, van Grootheest K: Experiences with adverse drug reaction reporting by patients: an 11-country survey. *Drug Saf* 2012, 35: 45-60.
111. Ahmad A, Patel I, Bal Krishnan R, Mohanta GP, Manna PK. An evaluation of knowledge, attitude and practice of Indian pharmacists towards adverse drug reaction reporting: A pilot study. *Perspect Clin Res* 2013; 4 (4): 204 - 210.

112. Fisher, S, Bryant, S.G. Postmarketing Surveillance - Accuracy of Patient Drug Attribution Judgments. *Clinical Pharmacology & Therapeutics* 2009; 48 (1): 102-107.
113. Dewitt, J.E, Sorofman, B.A. A model for understanding patient attribution of adverse drug reaction symptoms. *Drug Information Journal* 1999; 33 (3): 907-920.
114. Jarernsiripornkul N, Krska J, Capps P.A.G, Richards R.M.E, Lee A. Patient reporting of potential adverse drug reactions: a methodological study. *British Journal of Clinical Pharmacology* 2000; 53 (3):318-325.
115. Jarernsiripornkul N, Kakaew W, Loalukkana W, Krska J. Adverse drug reaction monitoring: comparing doctor and patient reporting for new drugs. *Pharmacoepidemiology and Drug Safety* 2009; 18 (3): 240-245.
116. Avery A.J et al. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys. *Health Technology Assessment* 2011; 15 (20): 1-234.
117. Barry C.A, Bradley C.P, Britten N, Stevenson F.A, Barber N. Patients' unvoiced agendas in general practice consultations: qualitative study. *British Medical Journal* 2000; 320 (7244): 1246-1250.
118. Biswas P, Biswas AK. Setting standards for proactive Pharmacovigilance in India: The way forward. *Indian Journal of Pharmacology* 2007; 39(3): 124-128.
119. Nichols V, Thériault-Dubé I, Touzin J, Delisle JF, Lebel D, Bussi eres JF, et al. Risk perception and reasons for noncompliance in pharmacovigilance: A qualitative study conducted in Canada. *Drug Saf.* 2009; 32:579–90.

120. Aziz Z, Siang TC, Badarudin NS. Reporting of adverse drug reactions: Predictors of under-reporting in Malaysia. *Pharmacoepidemiol Drug Saf.* 2007; 16:223–8.
121. Fadare JO, Enwere OO, Afolabi AO, Chedi BA, Musa A. Knowledge, attitude and practice of adverse drug reaction reporting among healthcare workers in a tertiary centre in Northern Nigeria. *Trop J Pharm Res.* 2011; 10:235–42.
122. Figueiras A, Herdeiro MT, Polónia J, Gestal-Otero JJ: An educational intervention to improve physician reporting of adverse drug reactions: a cluster- randomized controlled trial. *JAMA* 2006, 296:1086-1093.
123. Sott HD, Thacher-Renshaw A, Rosenbaun SE, Waters WJ Jr, Green M, Andrews LJ, Faich GA: Physician reporting of adverse drug reactions: results of the Rhode Island Adverse drug reaction reporting project. *Journal of American Medical Association* 1990, 263:1785-1788.
124. Eland IA, Belton KJ, Van Grootheest AC, Meiners AP, Rawlins MD, Rawlins MD, Stricker BH. Attitudinal survey of voluntary reporting of adverse drug reactions. *Br J Clin Pharmacol.* 1999 Oct; 48(4):623-7.
125. Belton KJ, Lewis SC, Payne S, Rawlins MD, Wood SM. Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom. *Br J Clin Pharmacol.* 1995 Mar; 39(3):223-6.
126. Blekinsopp, A., Wilkie, P., Wang, M., & Routledge, P, A. (2006). Patient reporting of suspected adverse drug reactions: A review of published literature and international experience. *British Journal of Clinical Pharmacology.* 63, 2, 148-156.

127. Aagaard L, Nielsen LH, Hansen EH. Consumer reporting of adverse drug reactions: a retrospective analysis of the Danish Adverse Drug Reaction Database from 2004 to 2006. *Drug Saf.* 2009; 32:1067–74.
128. Jha N, Rathore DS, Shankar PR, Gyawali S. Pharmacovigilance Knowledge among Patients at a Teaching Hospital in Lalitpur District, Nepal. *Journal of Clinical Diagnostic Research.* 2014 March; 8(3): 32-4.
129. Fortnum H, Lee AJ, Rupnik B, Avery A; Yellow Card Study Collaboration. Survey to assess public awareness of patient reporting of adverse drug reactions in Great Britain. *J Clin Pharm Ther* 2012; 37: 161-165.
130. WHO Collaborating Centre for Drug Statistics Methodology. Completed ATC Index 2005. <http://www.whocc.no/atcddd/>.
131. Edwards IR. Pharmacological basis of adverse drug reactions. In: Speight TM, Holford NHG, editors. *Avery's drug treatment.* 4th ed. Auckland, New Zealand: Adis International; 1997. p. 261–99.
132. Parthasarathi G, Sten Olsson. Adverse drug reactions. In: Parthasarathi G, Nyfort-Hansen K, Nahata MC, editors. *A text book of clinical pharmacy practice-essential concepts and skills.* 1st ed. Chennai: Orient Longman Private Limited; 2004. p. 86–102.
133. Veehof LJG, Stewart RE, Haaijer-Ruskamp FM, Meyboom-de Jong B. The development of polypharmacy. A longitudinal study. *Family Practice* 2000; 17(3):261–7.
134. European Commission. A guideline on summary of product characteristics, October 2005. <http://pharmacos.eudra.org/F2/eudralex/vol-2/C/SPCGuidRev0-Dec99.pdf>.



135. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. *Clin Pharmacol Ther* 1981; 30:239–45.
136. Schumock GT, Thornton JP. Focusing on the Preventability of Adverse Drug Reactions. *Hosp Pharm* June 1992; 27:538.
137. Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, et al. The cost of adverse drug events in hospitalized patients. *JAMA* 1997; 277:307-11.
138. American Society of Health System Pharmacists. ASHP guidelines on adverse drug reaction monitoring and reporting. *Am J Hosp Pharm* 1989; 46:336-7.
139. Rajesh R, Jayaprakash RS, Ramesh M, Pandey S, Thunga G, Sam K. A multi centre study on the nature and pattern of the occurrence of adverse drug reactions. *Journal of Clinical and Diagnostic Research*.
140. Ramesh M, Pandit J, Parthasarathi G. Adverse drug reactions in a South Indian hospital-their severity and cost involved. *Pharmacoepidemiol Drug Saf* 2003; 12:687–692.
141. Suh DC, Woodall BS, Shin SK, Hermes-De Santis ER. Clinical and economic impact of adverse drug reactions in hospitalized patients. *Ann Pharmacother*. 2000; 34: 1373-9.
142. Veehof LJ, Stewart RE, Meyboom-de Jong B, Haaijer- Ruskamp FM. Adverse drug reactions and polypharmacy in the elderly in general practice. *Eur J Clin Pharmacol*. 1999; 55: 533-6.
143. Lemozit JP, De La Rhodiere GP, Lapeyre-Mestre M, Bagheri H, Montastruc JL. A comparative study of adverse drug reactions reported through hospital and private medicine. *Br J Clin Pharmacol*. 1996; 41: 166-8.

144. Wu FL, Yang CC, Shen LJ, Chen CY. Adverse drug reactions in a medical ward. *J Formos Med Assoc.* 1996; 95: 241-6.
145. Pflanz S, Henderson IS, McElduff N, Jones MC. Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis. *Nephrol Dial Transplant.* 1994; 9 (8):1121-4.
146. Natalie H, Wade OL. Intensive hospital monitoring of adverse reactions to drugs. *Brit Med J.* 1969; 1: 531–536.
147. Bates DW, Leape LL, Petrycki S. Incidence and preventability of adverse drug events in hospitalized adults. *J Gen Intern Med* 1993; 8:289-94.
148. Gandhi TK, Weingart SN, Borus J, Seger AC, Peterson J, Burdick E, et al. Adverse drug events in ambulatory care. *N Eng J Med* 2003; 348:1156–64.
149. Evans RS, Lloyd JF, Stoddard GJ, Neberker JR, Samore MH. Risk factors for adverse drug events: a 10 year analysis. *Ann Pharmacother* 2005; 39:1161–8.
150. Fonescue EB, Kausbal R, Landrigan CP, McKenna KJ, Clapp MD, Federico F, et al. Prioritizing strategies for preventing medication errors and adverse drug events in pediatric inpatients. *Pediatrics* 2003; 111(4 Pt 1):722-9.
151. Field TS, Gurwitz JH, Avorn J, McCormick D, Jain S, Eckier M, et al. Risk factors for adverse drug events among nursing home residents. *Arch Intern Med* 2001; 161:1629–34.
152. Bates DW, Miller EB, Cullen DJ, Burdick L, Williams L, Laird N, et al. Patient risk factors for adverse drug events in hospitalized patients. *Arch Intern Med* 1999; 159:2553-9.

153. Rao PGM, Jose BAJ. Implementation and results of an adverse drug reaction reporting programme at an Indian teaching hospital. *Indian J Pharmacol* 2006 August; 38(4):293-4.
154. Murphy BM, Frigo LC. Development, implementation, and results of a successful multidisciplinary adverse drug reaction reporting program in a university teaching hospital. *Hosp Pharm* 1993; 28(12):1199–204, 1240.
155. Gonzalez-Martin G, Caroca CM, Paris E. Adverse drug reactions (ADRs) in hospitalized pediatric patients—a prospective study. *Int J Clin Pharmacol Ther* 1998; 36(10):530–3.
156. Kanjanarat P, Winterstein AG, Johns TE, Hatton RC, Gonzalez-Rothi R, Segal R. Nature of preventable adverse drug events in hospitals: a literature review. *Am J Health Syst Pharm* 2003; 60:1750-9.